Peptide Libraray

HS3

General Information

DCTPep ID DCTPep01041

Peptide Name HS3

Sequence CGAISLAKLQINES

Sequence Length 14

UniProt ID Not available

PubChem CID Not available

Origin Synthetic

Type Synthetic peptide

Classification

ACP Tumor active peptide Cancer targeted peptides

Activity Information

Cell Line	Disease	Activity	Assay	Testing Time	Literature
CT26	Mouse colon adenocarcinoma	IC50=80.7±6.9 µM	MTT assay	24, 48, 72h	1

Hemolytic Activity Not available

Normal (non-cancerous) Cytotoxicity Not available

Target programmed cell death protein 1

Affinity Not available

Mechanism Not available

Structure Information

PDB ID Not available

Predicted Structure DCTPep01041

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity Not available

Linear/Cyclic Linear

Disulfide/Other Bond Not available

N-terminal Modification Free

C-terminal Modification Free

Other Modification None

Chiral L

Physicochemical Information

Formula C61H107N17O21S1

Absent amino acids DFHMPRTVWY

Theoretical pI 5.99

Acidic residues 1

Basic residues 1

Polar residues 5

Molecular weight (Average) 1446.68

Molecular weight (Monoisotopic) 1445.75

Common amino acids AILS

Net charge 0

Instability index (II) 34.2

Aliphatic index 125.71

Grand average of hydropathicity (GRAVY) 0.450

Half Life
1.2 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).

Extinction coefficients
Ext. coefficient 0
Abs 0.1% (=1 g/l) 0.000, assuming all pairs of Cys residues form cystines
Ext. coefficient 0
Abs 0.1% (=1 g/l) 0.000, assuming all Cys residues are reduced

Amino acid distribution

Literature Information

Literature 1

Pubmed ID 33360579

Title Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy

Doi 10.1016/j.bmc.2020.115951

Year 2021

Patent

Patent ID Not available

Patent Title Not available

Other Iinformation Not available

Other Published ID Not available